Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ceftolozane/tazobactam versus meropenem for complicated urinary tract infection
2016-004153-32Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2017
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceftolozane, tazobactam, meropenem in complicated urinary tract infection (cUTI), pyelonephritis, sponsored by Merck & Co.. Started Jun 2017; status: completed.
02
Drugs
ceftolozanetazobactammeropenem
03
Conditions
complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on 2016-004153-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004153-32.